

# Advances in Radiation Oncology

## Virtual On Treatment Visits: Implementation, Patient Perspectives, Barriers, Limitations, Benefits and Opportunities

--Manuscript Draft--

<b>Manuscript Number:</b>	ADVANCESRADONC-D-20-00223R1
<b>Article Type:</b>	Scientific Article
<b>Section/Category:</b>	COVID-19
<b>Corresponding Author:</b>	Kevin Roof, MD Southeast Radiation Oncology Charlotte, NC UNITED STATES
<b>First Author:</b>	Kevin Roof, MD
<b>Order of Authors:</b>	Kevin Roof, MD
	Jerome M Butler, MD
	Vipul V Thakkar, MD
	Jeffrey G Kuremsky, MD
	Robert M Doline, MD
	John B Konefal, MD
	Robert J McCammon, MD
<b>Abstract:</b>	<p><b>Purpose :</b> To report our initial experience with weekly tele-video “virtual” on treatment visits (vOTVs), describe the logistics of implementation, report results of patient and physician surveys, and discuss barriers, limitations, and benefits of vOTVs during the COVID-19 pandemic.</p> <p><b>Method :</b> Virtual OTVs were piloted at two centers, and within one week expanded to 4 additional centers. Patients participating in vOTVs were surveyed about their satisfaction with vOTVs, quality of vOTVs, and confidence in their physician’s ability to manage their care through vOTVs, as well as their support of, and preferences related to vOTVs. Participating physicians were also surveyed about their comfort and satisfaction with vOTVs. Medical Directors at non-participating centers within our network were surveyed regarding their reasoning for not using vOTVs.</p> <p><b>Results :</b> In week 1, 72 of 81 patients between 2 pilot centers were seen using vOTVs. In week 2, 189 of 211 patients were seen using vOTVs at 6 centers. Patient satisfaction and confidence in their physician’s ability to address their concerns through the vOTV was high at 4.75 on a 5-point scale. Patients were overall very supportive (4.67) and found the quality of the visits to be as good as, or better, than their prior in person weekly OTV (3.75). Physicians participating in the vOTVs felt very comfortable in their ability to manage patients through this platform (5.0), and on average did not report any difference in terms of efficiency of visits (3.0).</p> <p><b>Conclusions :</b> Virtual OTVs were easy to implement and well received by patients and participating physicians. Our experience suggests that vOTVs can be implemented rapidly using available technology, and with a high degree of patient and physician satisfaction during this pandemic with similar efficiency to in person OTVs.</p>

Virtual On Treatment Visits: Implementation, Patient Perspectives, Barriers, Limitations, Benefits and Opportunities.

Kevin S. Roof, MD

Jerome M Butler, Jr., MD

Vipul V. Thakkar, MD

Robert M. Doline, M D

Jeffrey G. Kuremsky, MD

John B. Konefal, MD

Robert J McCammon, MD

Affiliation: Southeast Radiation Oncology Group, P.A.

Corresponding Author:

Kevin S. Roof, MD

200 Queens Road. Ste 400

Charlotte, NC 28204

[kroof@sero.net](mailto:kroof@sero.net)

(Office) 704-326-6630

(cell) 704-439-7424

Statistical Author: N/A

No Conflict of Interests to disclose

No funding provided

Not a clinical trial

We review our experience with virtual on treatment visits (vOTVs). We discuss, results surveys of patients and physicians involved and perspectives of physicians who chose not to participate. While use of vOTVs may be divisive, they do provide a way we can to protect our patients and our team members during this pandemic. Information related to their use is important to address concerns raised by those opposed to their use.

## Short Running Title: Virtual On Treatment Visits

### Virtual On Treatment Visits: Implementation, Patient Perspectives, Barriers, Limitations, Benefits and Opportunities

**Purpose:** To report our initial experience with weekly tele-video “virtual” on treatment visits (vOTVs), describe the logistics of implementation, report results of patient and physician surveys, and discuss barriers, limitations, and benefits of vOTVs during the COVID-19 pandemic.

**Method:** Virtual OTVs were piloted at two centers, and within one week expanded to 4 additional centers. Patients participating in vOTVs were surveyed about their satisfaction with vOTVs, quality of vOTVs, and confidence in their physician’s ability to manage their care through vOTVs, as well as their support of, and preferences related to vOTVs. Participating physicians were also surveyed about their comfort and satisfaction with vOTVs. Medical Directors at non-participating centers within our network were surveyed regarding their reasoning for not using vOTVs.

**Results:** In week 1, 72 of 81 patients between 2 pilot centers were seen using vOTVs. In week 2, 189 of 211 patients were seen using vOTVs at 6 centers. Patient satisfaction and confidence in their physician’s ability to address their concerns through the vOTV was high at 4.75 on a 5-point scale. Patients were overall very supportive (4.67) and found the quality of the visits to be as good as, or better, than their prior in person weekly OTV (3.75). Physicians participating in the vOTVs felt very comfortable in their ability to manage patients through this platform (5.0), and on average did not report any difference in terms of efficiency of visits (3.0).

**Conclusions:** Virtual OTVs were easy to implement and well received by patients and participating physicians. Our experience suggests that vOTVs can be implemented rapidly using available technology, and with a high degree of patient and physician satisfaction during this pandemic with similar efficiency to in person OTVs.

### **Introduction:**

COVID-19 can cause serious illness or death, particularly in high risk groups. Early data suggests cancer patients may be particularly vulnerable with death rates approaching 28% (1). Given the highly contagious nature of COVID-19, and the high mortality rate for cancer patients, significant efforts have been made to decrease infection risks for these patients. Efforts include: limiting visitors, screening patients, removing non-essential staff, and utilizing personal protective equipment (PPE). Additional measures include: postponing non-urgent visits, and treatments, with increased use of hypofractionation. Lastly, widespread adoption of telehealth consults and follow-up visits has been rapidly implemented. In an effort to further minimize patient, and staff risk of COVID-19 exposure, the American Society for Radiation Oncology (ASTRO) lobbied for coverage of virtual on treatment visits (vOTVs). On March 30, 2020 the Centers for Medicare & Medicaid Services (CMS) approved the use of telemedicine technology for weekly on treatment visits (OTVs) during this crisis (2).

For quality assurance purposes related to our launch of vOTVs we surveyed patients and physicians participating in vOTVs to identify potential problems and assess patient and physician satisfaction with vOTVs. Here we report the logistics of implementation of vOTVs, as well as results of patient and

physician surveys. We discuss potential barriers to implementation, benefits, and possible future opportunities.

### **Methods:**

Institutional Review Board authorization was provided based on this being an Evidence Based Practice project. Permission was granted to proceed with analysis for publication.

On March 30, 2020, CMS authorized use of telemedicine for management of radiation oncology patients under treatment (2). Immediately, thereafter, the executive committee of our group authorized piloting a trial of vOTVs at two centers. On March 31, 2020 vOTVs were performed independently at two centers. Both centers set up laptops in each exam room, and separate Zoom™ meetings (Zoom™ Video Communications, Inc, San Jose, CA) were initiated for each room from the physician's office. The Zoom™ meeting platform allowed real-time audiovisual interactions between providers in their offices, and patients in exam rooms. Patients were brought to the room by nurses during week 1. Nurses performed assessments, and evaluations of the patients including vital signs, and then reported to the physician office. The physician then joined the patient in the Zoom™ meeting, and completed the visit in the electronic medical record. Similar implementation was subsequently adopted at four other clinics during week 2. During week 2, two centers transitioned to a virtual nursing assessment for vOTVs as well. In one clinic patients were directed by radiation therapists (RTTs) to the appropriate exam room. The nurse joined the patient virtually in the Zoom™ meeting, completed assessments, and reported to the physician either via a separate Zoom™ meeting, or in person. The physician then entered the virtual exam room, and completed the visit. After the virtual visits were completed the nurse cleaned each room. The second center had the nurse perform assessments at the nursing station from a distance of 6 feet, and then the nurse would direct the patient to the appropriate exam room.

As part of a quality assurance effort patients were provided an anonymous 5-question survey (Figure 1), which they were asked to submit on their way out.

After the pilot trial, vOTVs were approved for use on a wider basis in our group.

Medical Directors at centers where vOTVs were not employed in week 2 were sent a survey about barriers to implementation, plans to employ vOTVs in the future, and specific concerns regarding vOTVs (Figure 2). Participating physicians were surveyed about their experience (Figure 3).

Each survey question with a numeric response was recorded. The numeric answers were multiplied by the number of responses with that number, summed, and then divided by the total number of responses to provide a mean response score for the question. Surveys in which the question was not answered were excluded from analysis for that specific question. Averages were initially obtained by center. All surveys were then averaged as a combined average score. The averages by center were presented as a range around the combined average.

### **Results:**

#### **Implementation Results:**

In week 1, two centers participated in the pilot of vOTVs. A total of 72/81 OTVs (89%) were seen exclusively via tele-video visit, 30/34 and 42/47, respectively. During the second week, 5 additional centers performed vOTVs. 4 of these 5 centers performed vOTVs on the majority of patients, while the

fifth center used vOTVs on only a few patients. 2 of the 4 additional centers that performed vOTVs on the majority of patients during week 2 distributed patient surveys. Between the 6 centers using vOTVs regularly in week 2, a total of 189 of 211 OTVs (90%; Range 77-100%) were seen exclusively through vOTVs. 130 of the 140 patients (93%) offered surveys between week 1 and 2, completed the survey. Surveys were offered to all patients in 1 center in weeks 1 and 2. Surveys were anonymous, and it was not clear which patients had or had not completed the surveys. It is possible some patients may have completed the survey in both week 1 and 2 at that center. Of the 31 patients not seen virtually the reasons for in person visits included: need for more detailed exams (9) {skin exam (5), and head/neck exam (4)}, and communication difficulties (7) {translator services (3), laryngectomies (2), hard of hearing (1), need for family member to participate by phone (1)}. Technical problems accounted for 4 in person visits, while admitted patients (3), syncope (1), patient request (1) and other medical problems, not specified (6) accounted for the remaining in person visits. It is the authors' observation that patients most likely to need in person assessments were breast or head and neck cancer patients in later phases of therapy or those with communication barriers. It is worth noting demographics, tumor type, treatment specifics were not recorded. Surveys were anonymous.

#### **Patient Survey Results (Figure 4):**

**Question 1.** Please rate your satisfaction with your telemedicine visit? 128 of 130 (98.5%) of survey respondents answered this question. The combined average score for this question was 4.75 of 5. 97% of patients recorded a score of 4 = satisfied (18%) or 5 = very satisfied (79%). There was 1 patient (0.8%) who responded that they were dissatisfied. This patient answered the remainder of the questions very positively; suggesting possible confusion about question 1. This high level of patient satisfaction was consistent across centers with center averages on this question ranging from 4.7-4.9.

**Question 2.** How did you feel about the quality of this visit as compared to prior weekly visits with your radiation oncologist? There was the option to check N/A if this was the patient's first OTV. Of note, Centers B and C modified this question to allow only 3 answers, 1 = Worse, 2 = No difference, 3 = Better. For grading purposes on this version of the survey a 2 was correlated to a 3 (no difference), and a 3 was correlated to a 5. Ten respondents selected N/A and 2 respondents failed to answer this question. 118 of 130 respondents (91%) answered the question. The combined average score for this question was 3.75 of 5 with center averages ranging from 3.4-4.2. Most notably, no respondents reported the quality of the visit as worse than their prior in-person weekly visit.

**Question 3.** How confident did you feel your doctor was able to address your concerns equally effectively using this platform compared to an in person visit? 129 of 130 respondents (99%) answered this question. The average score was 4.74 with a range of 4.6-4.84 between centers. 94% of respondents felt confident to very confident the physician could address concerns equally effectively through tele-video visits as in person. Only 1 person responded with a less than neutral response of somewhat confident (score of 2), while 7 reported being neutral (score of 3) about their physician's ability to equally effectively manage their care with a vOTV.

**Question 4:** How supportive are you of using tele-video visits for your weekly visit during the COVID-19 pandemic? 129 of 130 respondents (99%) answered this question. The average response was 4.67 out of 5. The range of averages for centers was 4.58-4.87. 121 of 129 respondents (94%) reported being supportive (score of 4) or very supportive (score of 5). 5% reported being neutral (score of 3) and 1% reported being somewhat supportive (score of 2).

**Questions 5:** If given the choice, would you rather see another physician provider in the room in-person each week or would you rather see your regular radiation oncologist through a tele-visit weekly (there would be a provider on site if you needed medical attention immediately)? This question was based on the implementation of an alternating physician staffing schedule during the COVID-19 pandemic. Physician partners alternated between clinic and remote coverage during this phase of the pandemic. 128 of 130 respondents (98%) answered this question. 46% had no preference, 25% preferred to always see their own physician by tele-medicine rather than see any MD in person, and 21% preferred to see their own MD via telemedicine most weeks even if it meant an occasional different physician by telemedicine some weeks. Less than 10% of patients responded with a score suggesting they would prefer to see a physician in person rather than do tele-video visits.

### **Non-Participating Medical Director Survey Results (**

Surveys were sent to medical directors at 13 centers where it was not clear that virtual OTVs were performed. Two centers reported they had performed vOTVs on the majority of patients, but had not distributed the surveys. A third center reported that they had performed virtual OTVs on some patients, but had not utilized it in the majority of patients, and had not distributed surveys. The medical director of the latter center cited concerns over the logistical difficulties in a busy multi-machine center with multiple patient exam rooms, lack of overall physician enthusiasm, and concern over potential adverse response to physician conversion to vOTVs by patient facing staff (nurses and therapists). This center planned to continue to use vOTVs on a case by case basis moving forward. Six of the 10 medical directors responded that they did not utilize vOTVs due to a lack of required hardware (primarily cameras or computers in exam rooms). Two of 10 Medical Directors cited not having hospital authorized software in place to perform the vOTV. 2 Medical Directors did not see a distinct advantage to doing vOTVs as opposed to an in person visit with PPE from a distance. In the other comments section: 3 medical directors expressed concerns over the optics of having nurses and radiation therapists interfacing with patients, while physicians saw patients virtually, and one expressed concerns over the efficiency of vOTVs.

Nine of the 10 medical directors where vOTVs were not used responded that they did not plan to utilize vOTVs in the immediate future, while 5 of 10 suggested they intended to utilize vOTVs at some point, if needed. Specific concerns raised by the medical directors about use of vOTVs included: concerns over their ability to adequately examine patients, beliefs about patient dissatisfaction with vOTVs, questions about the benefit, and concerns over optics.

### **Survey Results of Physicians Participating in Tele-video OTVs**

7 physicians who used vOTVs for the majority of their patients under treatment were surveyed about their experience. Physicians reported their comfort level in their ability to manage patients through vOTVs to be very confident (score of 5) in all cases. Similarly, 7 of 7 physicians reported feeling comfortable or very comfortable performing vOTVs remotely as long as there was another practitioner in the office available to perform assessments as needed. Physicians were mixed in their comfort with the idea of using virtual OTVs to manage patients if there was not a clinician on site to perform live assessments as needed. The average score was 2.7, but 2 physicians reported scores of 5 and 2 reported scores of 1. In terms of efficiency there was a mix of opinions with 3 physicians reporting the process to be slightly less efficient and 3 reporting the process to be slightly more efficient, and 1 reporting no difference. (Figure 3)

## **Discussion:**

The COVID-19 pandemic lead CMS to temporarily de-regulate the use of telemedicine to encourage social distancing and help minimize the risk of disease transmission. In addition to allowing for consultation and follow-up visits, CMS also authorized the use of telemedicine for radiation oncology weekly patient under treatment visits (2). Telemedicine use in radiation oncology in the United States prior to the COVID-19 pandemic was extremely limited based on all available information. There are reports of its use for multidisciplinary tumor boards, conferences, radiation treatment planning, and follow-up visits (3, 4). However we believe this is the first report on the use of telemedicine for radiation oncology patient under treatment visits.

Based on our nonparticipating medical director surveys as well as public comments on ASTRO's open forum, perceived barriers to widespread adoption of vOTVs include: Lack of hardware / software, concerns about quality of vOTVs. Specifically, concerns about physicians' ability to perform an appropriate assessment of the patient, or the physician's ability to provide emotional support. Additional barriers include: Concerns about efficiency, and the optics of physicians performing vOTVs while other frontline workers face daily exposures (5). Finally, some failed to appreciate the advantages of vOTVs compared to in person OTVs.

Herein, we address each of these concerns in hopes that in doing so we may encourage others to consider utilizing vOTVs to increase social distancing, and help suppress COVID-19 transmission between patients, physicians and staff.

CMS' relaxation of HIPAA compliance requirements for telemedicine platforms during COVID-19 has resulted in hardware and software requirements necessary to perform vOTVs being low cost, and readily available (6). Hardware requirements include: Internet connectivity, a minimum of 2 computers with camera, and microphone capabilities. Software requirements are also minimal, and are freely available. Although we used Zoom™, CMS' requirements allow use of many systems including Microsoft Teams™, Blue Jeans™, Face Time™, Messenger™, or other tele-video systems. Software and hardware requirements to perform vOTVs are relatively inexpensive, and readily available. Technology should not present a barrier to implementation of vOTVs.

Next, results of our patient and physician surveys demonstrated high patient satisfaction with vOTVs. The perception of the quality of the vOTV was as good if not better than in person OTVs. Of 130 surveys completed none reported the vOTV quality as being inferior to the preceding weeks in person OTV. There were no complaints about visit feeling detached or patients feeling unsupported.

Our participating physician survey results suggest these physicians felt comfortable and confident in their ability to perform appropriate weekly assessments in the majority of patients through this platform. The four basic components of CPT 77427 as defined by CMS include: Review of port film or other imaging, review of dosimetry, dose delivery and treatment parameters; examination of the patient set up; examination of the patient for medical evaluation, and case management (7).

The key issue here is whether the examination of the patient for medical evaluation can be appropriately performed through a virtual visit. CMS does not specify which components of the physical examination are required for medical evaluation of these patients. Clearly, the exam requirements should vary based on patient, disease site treated, time point in course of therapy, and symptoms. In



our study, approximately 90% of patients were evaluated by the physician exclusively through the virtual visit. It is important to note, however, that the vast majority of our patients were outpatients with a good performance status. Also, they had a general assessment before entering the department. All admitted patients or unstable patients were evaluated in person. We believe most stable outpatients can be adequately assessed through vOTVs.

The most common reasons for in person evaluations included the need for more detailed skin examination, head and neck examination, language barriers, or emotional or medical instability requiring in person evaluation and management. Some of these limitations are being addressed with developing technology such as virtual stethoscopes, otoscopes, and tongue depressors with cameras. None of these advanced technologies were available in our clinic. In addition to the aforementioned advances in virtual technology, high-quality computer cameras in the exam rooms as well as good exam room lighting should also help address concerns about the quality of the exams.

In reference to efficiency, these visits were felt on average to be equally efficient as in person visits. While there was some inefficiency early in the process, those who had more than 1 week of experience reported the experience as more efficient. 1 respondent who answered that it was less efficient cited the need to explain why vOTVs were necessary as the only reason the visit was less efficient.

Although there are concerns about the optics of physicians and nurses using virtual technology to protect themselves while therapists serve on the front lines without any such protection, it defies logic to argue that we should not protect some because we cannot protect all. As low as reasonably allowable (ALARA) means that if an exposure can be safely minimized, whether it is to radiation or a virus, it should be. It does not mean if some exposures cannot be limited efforts should not be taken to minimize other exposures. Every individual interaction eliminated is one less chance of infecting a patient or team member who could then potentially infect the whole team. The idea of using vOTVs only if you are sick is flawed in light of the known risk of asymptomatic carrier transmission. Unnecessarily exposing patients to COVID-19, including exposure via an asymptomatic infected provider, is unjustifiable. In person OTVs are not medically necessary for proper patient management in the majority of cases. While the historical norm is to be physically present with our patients, telemedicine allows us to provide equally compassionate care and support to our patients without physical proximity. This protects not only our patients, but our staff and ourselves.

In addition to the benefit of decreasing the risk of infecting patients with COVID-19 by decreasing exposure to healthcare workers, vOTVs also afford other benefits. Visitors, currently restricted in our cancer center, are able to participate in loved one's vOTVs. Moreover, translators, nutritionist, social workers, and other ancillary staff can easily participate in vOTVs remotely. Additionally vOTVs allow providers who may be quarantined or working remotely to continue to provide care for their patients.

These virtual visits have only been authorized during this pandemic. While it is authorized, physicians should feel comfortable utilizing this technology for most, but perhaps not all of their patients under treatment. It is likely there will be a public outcry for continuation of telemedicine benefits following the pandemic. Physicians should continue to assess how we can use this technology to better serve our patients. Further research could help advance this technology whereby potentially all patients could be seen virtually with assistance from wearable devices, virtual stethoscopes, and improvements of camera quality. Such advancements could improve access to radiation oncology site specific sub-specialists, and or improve access to clinical trial participation. Finally, with CMS's recent changes to direct supervision

requirements, and a potential upcoming shortage of radiation oncologists this technology could afford more flexibility in staffing solutions to address those shortages as needed (8, 9).

Potential problems with our study include that it was performed very early after the adoption of the technology potentially resulting in lower efficiency and patient satisfaction scores than might have been obtained after practitioners had become more adept at using the system, and patients had become more accustomed to the technology. Alternatively, its implementation occurred just prior to the anticipated surge in our state, and patients' willingness to accept vOTVs may have been higher at that time than it will be as the crisis continues. Another problem was that there were slight variations in the survey between health care systems as this was launched as a QA process rather than a study. These differences in questions complicated interpretation of the results, but we believe the overall message of the results were not impacted.

Radiation oncologists learn early in training about the importance of time, distance and shielding to minimize exposure to radio-isotopes. We can apply those same principals to exposure to this virus. Virtual OTVs allow us to dramatically increase our distance from the source, and significantly decrease our time exposed to the source when in person assessments are necessary. PPE provides shielding when we do need to interact with patients. However, PPE is not perfect protection. Time and distance are our best defenses. We should all be doing everything possible to keep our exposure ALARA. Given experts anticipate a second wave coinciding with influenza in the fall, using vOTVs in addition to virtual consults, and follow ups to minimize our exposure risks to both of these vectors seems prudent, and should be strongly considered (10).

## References:

1. Zang L, Zhu, F, et al. (In Press). Clinical characteristics of COVID-19 infected cancer patients: a retrospective case study in three hospitals in Wuhan, China. *Annals of Oncology*. doi: 10/1016/j.annonc.2020.03.296
2. Centers for Medicare and Medicaid Services. (2020, May 13). Physicians and Other Clinicians: CMS Flexibility to Fight COVID-19. <https://www.cms.gov/files/document/covid-19-physicians-and-practitioners.pdf>
3. Hamilton E, Van Veldhuizen E, et al. Telehealth in radiation oncology at the Townsville Cancer Centre: Service evaluation and patient satisfaction. *Clin Transl Radiat Oncol*. 2019; 15:20-25.
4. Lewis GD, Hatch SS, et al. Long-term institutional experience with telemedicine services for radiation oncology: A potential model for long-term utilization. *Adv in Rad Onc*. 2020; 5: 780-782.
5. Potters L. (2020, May 18). Continued observations from the epicenter: Time for the ALARA alarm. Retrieved from <https://rohub.astro.org/communities/community-home/digestviewer>.
6. United States Department of Health and Human Services. Telehealth. Delivering Care Safely through COVID-19. Accessed August 29, 2020. Retrieved from <https://www.hhs.gov/coronavirus/telehealth/index.html>.
7. Centers for Medicare and Medicaid Services. Billing and Coding Guidelines for Radiation Oncology including Intensity Modulate Radiation Therapy (IMRT). Accessed August 29, 2020. Retrieved from [https://downloads.cms.gov/medicare-coverage-database/lcd\\_attachments/34652\\_13/L34652\\_RAD014\\_BCG.pdf](https://downloads.cms.gov/medicare-coverage-database/lcd_attachments/34652_13/L34652_RAD014_BCG.pdf).
8. Centers for Medicare and Medicaid Services. Medicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Revisions of Organ Procurement Organizations Conditions of Coverage; Prior Authorization Process and Requirements for certain covered outpatient department services; Potential changes to the laboratory date of service policy; Changes to Grandfathered Children's Hospitals-Within-Hospitals; Notice of Closure of Two Teaching Hospitals and Opportunity To Apply for Available Slots 2019. <https://www.federalregister.gov/documents/2019/11/12/2019-24138/medicare-program-changes-to-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center>. Accessed August 1, 2020.
9. Yang W, Williams JH, et al. Projected supply of and demand for oncologists and radiation oncologists through 2025: An aging and better-insured population will result in shortage. *Journal of Oncology Practice*. 2014 10:1, 39-45.
10. Sum, Lena. "CDC Director Warns Second Wave of Coronavirus Is Likely to Be Even More Devastating." *The Washington Post*, 2020, [www.washingtonpost.com/health/2020/04/21/coronavirus-secondwave-cdcdirector/](http://www.washingtonpost.com/health/2020/04/21/coronavirus-secondwave-cdcdirector/).

Figure 1. Survey distributed to patients as part of initial QA for vOTVs. Survey was modified at two centers such that question 2 was modified to just 3 choices, 1 = worse, 2 = no difference 3= better. Question 4 was modified to 4 responses 1= Not supportive, 2 = Somewhat supportive 3 = Neutral Supportive 4= Very supportive.

Figure 2. Non-participating medical director survey. The circle indicates the average response. The average response for question 3 was 2.7.

Figure 3. Participating physicians survey with averaged response results.

Figure 4. Survey responses. For surveys in which questions 2 and 4 were modified, on question 2 scores of 2 were given a score of 3 and scores of 3 were given score of 5. For question 4 scores of 3 were given a score of 3, and scores of 4 were given a score of 5.

**Figure 1****Question 1**

Please rate your satisfaction with your telemedicine visit.

---

1	2	3	4	5
Very Dis-Satisfied	Dis-Satisfied	Neutral	Satisfied	Very Satisfied

**Question 2**

How did you feel about the quality of this visit as compared to prior weekly visits with your radiation oncologist?

---

1	2	3	4	5
Experience was Worse		No Difference		Experience was Better

**Question 3**

How confident did you feel your doctor was able to address your concerns equally effectively using this platform compared to an in person visit?

---

1	2	3	4	5
Not Confident	Somewhat Confident	Neutral	Confident	Very Confident

**Question 4**

How supportive are you of using televisits for your weekly visit during the COVID-19 pandemic?

---

1	2	3	4	5
Not Supportive	Somewhat Supportive	Neutral	Supportive	Very Supportive

**Question 5**


If given the choice, would you rather see another physician provider in the room in person each week or would you rather see your regular radiation oncologist through a tele-visit weekly (there would be a provider available on site if you needed immediate in person attention)?

1. See different physician in person rather than any tele-visits
2. See different MD some weeks as long as could see my MD in person some weeks
3. No preference
4. Prefer to see my own physician via telemedicine most weeks with occasional different MD
5. Prefer to always see my own physician by telemedicine and not see any MD in person


Figure 2

- 1) What was the primary reason you did not utilize virtual OTVs the week of April 6?
  - A. Health System did not have approve of use of available software to allow virtual OTVs.  
If "A" do they plan to obtain or have they obtained software system to allow use of virtual OTVs? Yes or No
  - B. Health System did not have the hardware (cameras/microphones in rooms) in place to allow virtual OTVs.  
If "B" does your healthcare system plan to obtain necessary hardware to allow virtual OTVs? Yes or No
  - C. Lack of knowledge on how to set up virtual OTVs.  
If "C", would you be willing and able to perform virtual OTVs if you were educated as to how to perform? Yes or No. If no why not?
  - D. Did not perform due to RN or RTT discomfort with virtual OTVs.  
If "D" was it RN, RTT or both that were cause of concern?
  - E. I would have and could have performed virtual OTVs, but I was unaware this was an option.
- 2) Are you planning to utilize virtual OTVs at your center this week? Yes or No
- 3) Do you plan to use virtual OTVs at any point? Yes or No
- 4) Do you have specific concerns about the use of virtual OTVs? Yes or No  
If so, please elaborate.


1. How confident were you in your ability to manage patients through the tele-video OTV knowing that you could enter the room at any time?




2. What would be your comfort level performing OTVs from a remote site if there was another practitioner on site to evaluate patients in person as needed?



3. What would be your comfort level in performing tele-video OTVs from a remote site without another practitioner on site to evaluate the patients in person as needed?



4. How would you rate the efficiency of the OTV compared to a live in the room OTV?



5. Please provide any comments including benefits or concerns about your experience using tele-video technology for OTVs.

Figure 2

